Cargando…
Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literat...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/ https://www.ncbi.nlm.nih.gov/pubmed/33981507 http://dx.doi.org/10.7759/cureus.14387 |
_version_ | 1783689862754336768 |
---|---|
author | Thomas, Rachel Patel, Hamish Scott, Joshua |
author_facet | Thomas, Rachel Patel, Hamish Scott, Joshua |
author_sort | Thomas, Rachel |
collection | PubMed |
description | Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis. |
format | Online Article Text |
id | pubmed-8106943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-81069432021-05-11 Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma Thomas, Rachel Patel, Hamish Scott, Joshua Cureus Dermatology Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis. Cureus 2021-04-09 /pmc/articles/PMC8106943/ /pubmed/33981507 http://dx.doi.org/10.7759/cureus.14387 Text en Copyright © 2021, Thomas et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Thomas, Rachel Patel, Hamish Scott, Joshua Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title | Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title_full | Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title_fullStr | Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title_full_unstemmed | Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title_short | Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma |
title_sort | dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/ https://www.ncbi.nlm.nih.gov/pubmed/33981507 http://dx.doi.org/10.7759/cureus.14387 |
work_keys_str_mv | AT thomasrachel dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma AT patelhamish dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma AT scottjoshua dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma |